Search Within

David Hyman

  1. "Maurizio Scaltriti"
Formats
  1. Journal Article (16)
  2. Meeting Abstract (10)
  3. Research Letter (1)
Groups
  1. Department of Medicine (27)
  2. Early Drug Development Service (27)
  3. Solid Tumor Oncology Division (27)
  4. GSK Faculty (25)
  5. Hematology-Oncology Fellows (23)
  6. Human Oncology and Pathogenesis Program (21)

More Groups

People
  1. Maurizio Scaltriti (27)
  2. Michael Berger (14)
  3. Alexander Drilon (13)
  4. Alison Schram (13)
  5. Emiliano Cocco (13)
  6. Jaclyn Hechtman (13)

More People

Years
  1. 2022 (1)
  2. 2021 (2)
  3. 2020 (8)
  4. 2019 (5)
  5. 2018 (8)
  6. 2017 (2)

More Years

Publications
  1. Cancer Research (6)
  2. Cancer Discovery (5)
  3. Clinical Cancer Research (4)
  4. Journal of Clinical Oncology (3)
  5. Annals of Oncology (1)
  6. Blood (1)

More Publications

Publishers
  1. American Association for Cancer Research (15)
  2. American Society of Clinical Oncology (3)
  3. Nature Publishing Group (3)
  4. American Association for the Advancement of Science (1)
  5. American Society for Clinical Investigation (1)
  6. American Society of Hematology (1)

More Publishers

Results (27)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • The evolution of RET inhibitor resistance in RET-driven lung and thyroid cancers
    Journal Article

    Rosen, E. Y.; Won, H. H.; Zheng, Y.; Cocco, E.; Selcuklu, D.; Gong, Y.; Friedman, N. D.; de Bruijn, I.; Sumer, O.; Bielski, C. M.; more...
    Nature Communications (2022)

    Fulltext@MSK | Save
  • Phase I basket study of taselisib, an isoform-selective PI3K inhibitor, in patients with PIK3CA-mutant cancers
    Journal Article

    Jhaveri, K.; Chang, M. T.; Juric, D.; Saura, C.; Gambardella, V.; Melnyk, A.; Patel, M. R.; Ribrag, V.; Ma, C. X.; Aljumaily, R.; more...
    Clinical Cancer Research (2021)

    Fulltext@MSK | Save
  • TRK XDFG mutations trigger a sensitivity switch from type I to II kinase inhibitors
    Journal Article

    Cocco, E.; Lee, J. E.; Kannan, S.; Schram, A. M.; Won, H. H.; Shifman, S.; Kulick, A.; Baldino, L.; Toska, E.; Arruabarrena-Aristorena, A.; more...
    Cancer Discovery (2021)

    Fulltext@MSK | Save
  • Kinase fusions drive endocrine resistance in estrogen receptor-positive breast cancer
    Meeting Abstract

    Liu, B.; Ross, D. S.; Schram, A. M.; Razavi, P.; Lagana, S. M.; Zhang, Y.; Scaltriti, M.; Bromberg, J. F.; Ladanyi, M.; Hyman, D. M.; more...
    Cancer Research (2020)

    Fulltext@MSK | Save
  • TRK xDFG mutations trigger a sensitivity switch from type I to II kinase inhibitors
    Meeting Abstract

    Cocco, E.; Lee, J. E.; Kannan, S.; Schram, A. M.; Won, H. H.; Shifman, S.; Kulick, A.; Baldino, L.; Toska, E.; Arena, S.; more...
    Cancer Research (2020)

    Fulltext@MSK | Save
  • Enrichment of kinase fusions in ESR1 wild-type, metastatic breast cancer revealed by a systematic analysis of 4854 patients
    Journal Article

    Ross, D. S.; Liu, B.; Schram, A. M.; Razavi, P.; Lagana, S. M.; Zhang, Y.; Scaltriti, M.; Bromberg, J. F.; Ladanyi, M.; Hyman, D. M.; more...
    Annals of Oncology (2020)

    Fulltext@MSK | Save
  • Capivasertib, an AKT kinase inhibitor, as monotherapy or in combination with fulvestrant in patients with AKT1(E17K)-mutant, ER-positive metastatic breast cancer
    Journal Article

    Smyth, L. M.; Tamura, K.; Oliveira, M.; Ciruelos, E. M.; Mayer, I. A.; Sablin, M. P.; Biganzoli, L.; Ambrose, H. J.; Ashton, J.; Barnicle, A.; more...
    Clinical Cancer Research (2020)

    Fulltext@MSK | Save
  • Landscape and outcome of TRK fusion-positive cancers
    Meeting Abstract

    Rosen, E. Y.; Goldman, D. A.; Hechtman, J. F.; Benayed, R.; Schram, A. M.; Cocco, E.; Shifman, S.; Gong, Y.; Kundra, R.; Solomon, J. P.; more...
    Clinical Cancer Research (2020)

    Fulltext@MSK | Save
  • HER2-mediated internalization of cytotoxic agents in ERBB2 amplified or mutant lung cancers
    Journal Article

    Li, B. T.; Michelini, F.; Misale, S.; Cocco, E.; Baldino, L.; Cai, Y.; Shifman, S.; Tu, H. Y.; Myers, M. L.; Xu, C.; more...
    Cancer Discovery (2020)

    Fulltext@MSK | Save
  • TRK fusions are enriched in cancers with uncommon histologies and the absence of canonical driver mutations
    Journal Article

    Rosen, E. Y.; Goldman, D. A.; Hechtman, J. F.; Benayed, R.; Schram, A. M.; Cocco, E.; Shifman, S.; Gong, Y.; Kundra, R.; Solomon, J. P.; more...
    Clinical Cancer Research (2020)

    Fulltext@MSK | Save